Impact of visually identified in-stent protrusion on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction
Cardiovascular Intervention and Therapeutics · 2026
DOI: 10.1007/s12928-025-01199-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Intervention and Therapeutics, 2026. Verfasst von Taku Kasahara und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya, Saitama City, 330-8503, Japan. Hauptthemen laut MEDLINE: ST Elevation Myocardial Infarction, Stents, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
In-stent protrusion is sometimes observed after the stent implantation to the culprit lesion of ST-segment elevation myocardial infarction (STEMI). However, it remains unclear whether additional interventions are necessary for non-obstructive in-stent protrusions. The purpose of this retrospective study was to compare clinical outcomes of patients with STEMI between with and without angiographically visible in-stent protrusions, and to evaluate the association between angiographically visible in-stent protrusions and long-term clinical outcomes in patients with STEMI. We included 639 patients with STEMI who underwent stent implantation and divided them into the protrusion group (n = 59) and the clear stent group (n = 580). In-stent protrusion was defined as an angiographically visible in-stent contrast filling defect at final angiography. The primary endpoint was major adverse cardiovascular events (MACE), which were defined as the composite of all cause death, non-fatal myocardial infarction, and ischemia-driven target vessel revascularization. During the median follow-up duration of 620 (213-1379) days, MACE were more frequently observed in the protrusion group than in the clear stent group (p = 0.002). The multivariate Cox hazard analysis revealed that in-stent protrusion was significantly associated with MACE after controlling for multiple confounding factors (HR 2.373, 95% CI 1.311-4.294, p = 0.004). In conclusion, angiographically visible in-stent contrast filling defect at final angiography is a marker for worse clinical outcomes in primary PCI. When interventional cardiologists recognize visible irregular protrusion after stent implantation for STEMI, additional intervention or careful clinical follow up may be needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya, Saitama City, 330-8503, Japan.
- Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma, Omiya, Saitama City, 330-8503, Japan. ksakakura@jichi.ac.jp.
Zitieren
APA
Kasahara, T., Sakakura, K., Jinnouchi, H., Taniguchi, Y., Yamamoto, K., Tsukui, T., Hatori, M., Watanabe, Y., Ishibashi, S., Seguchi, M., & Fujita, H. (2026). Impact of visually identified in-stent protrusion on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction. Cardiovascular Intervention and Therapeutics. https://doi.org/10.1007/s12928-025-01199-2
Vancouver
Kasahara T, Sakakura K, Jinnouchi H, Taniguchi Y, Yamamoto K, Tsukui T, et al. Impact of visually identified in-stent protrusion on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction. Cardiovascular Intervention and Therapeutics. 2026. doi:10.1007/s12928-025-01199-2
BibTeX
@article{Kasahara2026,
author = {Kasahara, Taku and Sakakura, Kenichi and Jinnouchi, Hiroyuki and Taniguchi, Yousuke and Yamamoto, Kei and Tsukui, Takunori and Hatori, Masashi and Watanabe, Yusuke and Ishibashi, Shun and Seguchi, Masaru and Fujita, Hideo},
title = {Impact of visually identified in-stent protrusion on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction},
journal = {Cardiovascular Intervention and Therapeutics},
year = {2026},
doi = {10.1007/s12928-025-01199-2}
}
EUVIMED